The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial
المصدر
Iranian Red Crescent Medical Journal
العدد
المجلد 20، العدد 7 (31 يوليو/تموز 2018)، ص ص. 1-7، 7ص.
الناشر
تاريخ النشر
2018-07-31
دولة النشر
الإمارات العربية المتحدة
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background: Obsessive-compulsive disorder (OCD) is the fourth common psychiatric disorder.
Among the anxiety disorders, OCD has the least therapeutic response and 40-60% of OCD patients do not satisfactorily respond to the first-line standard treatment known as treatment-resistant OCD.
One of the best therapeutic strategies is the augmentation therapy, which is adding antipsychotics to the standard treatment (SSRIs).
Objectives: This study was aimed at comparing the efficacy of Risperidone and Aripiprazole as augmentation therapy in the resistant cases of obsessive-compulsive disorder.
Methods: In this double-blind randomized clinical trial, 100 patients with treatment-resistant OCD were diagnosed based on the DSM-IV-TR and were followed for 12-weeks.
The patients were randomly divided into two groups of Aripiprazole and Risperidone and received an average daily dose of 5 mg and 1.5 mg for twelve weeks, respectively.
The efficacy of treatment was measured and compared by the Yale-brown obsessive-compulsive scale (Y-BOCS) at 4, 8 and 12 weeks.
Results: The mean Y-BOCS score of patients in Risperidone and Aripiprazole groups were 25.26 ± 4.17 and 25.02 ± 4.46; respectively and had no significant difference (P = 0.79) at the beginning of the trial.
At the end of the study (12th week), it was changed for the Risperidone and Aripiprazole groups to 20.00±4.45 and 16.24±4.41, respectively (P < 0.001).
Furthermore, there was a significant decreasing trend of Y-BOCS scores in both groups, which was demonstrated by the repeated measurement analysis (P < 00.1).
Conclusions: It was found that both Aripiprazole and Risperidone could be effective in the treatment of treatment-resistant OCD patients.
However, Aripiprazole showed a higher efficacy compared to Risperidone.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Assarian, Fatimah& Ghurishi, Fatimah Sadat& Burna, Mahbubah& Razzaghuf, Muhammad Rida. 2018. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal،Vol. 20, no. 7, pp.1-7.
https://search.emarefa.net/detail/BIM-903561
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Assarian, Fatimah…[et al.]. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal Vol. 20, no. 7 (Jul. 2018), pp.1-7.
https://search.emarefa.net/detail/BIM-903561
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Assarian, Fatimah& Ghurishi, Fatimah Sadat& Burna, Mahbubah& Razzaghuf, Muhammad Rida. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal. 2018. Vol. 20, no. 7, pp.1-7.
https://search.emarefa.net/detail/BIM-903561
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 6-7
رقم السجل
BIM-903561
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر